A Phase 3 interventional study of placebo and pregabalin in Diabetic Neuropathy, Painful, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 49 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing pregabalin in Diabetic Neuropathies — 1 open to participants now, 1 under way, 1 of them phase 3. Pregabalin · Diabetic Neuropathies.
Among the 17 studies testing pregabalin in Diabetic Neuropathies, this one is the 8th largest by enrollment, is one of 2 that started in 2007, is one of 10 in phase 3, and was the 7th registered.
539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
Browse Diabetic Neuropathies studies →1 of the 17 studies testing pregabalin in Diabetic Neuropathies is open now, in 1 country. Recruiting first, the newest first:
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 314 is above the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.
Median enrollment 241 across the 17 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 7 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
12 studies in Diabetic Neuropathies by Viatris Inc.: none open now, none under way, none of them phase 3. Of 12 finished, 5 (42%) have results posted.
Among the 12 studies in Diabetic Neuropathies by Viatris Inc., this one is the 6th largest by enrollment, is the only one that started in 2007, is one of 8 in phase 3, and was the 6th registered.
Viatris Inc.’s Diabetic Neuropathies studies by the year they started, since 1998.
1 of the studies testing pregabalin in Diabetic Neuropathies that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing pregabalin in Diabetic Neuropathies, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 12 in Diabetic Neuropathies:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of pregabalin at 300 mg/day and 600 mg/day (BID) in patients with painful diabetic peripheral neuropathy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: placebo
Drug: pregabalin
Drug: pregabalin
Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
Change From Baseline to Study Endpoint in Mean Weekly Pain Scores
Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations
Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr).
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Number of Responders
A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline at Week 1 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1. Change from baseline: Score at Week 1 minus score at baseline
Time frame: From baseline to Week 1
Change From Baseline at Week 2 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2. Change from baseline: Score at Week 2 minus score at baseline
Time frame: From baseline to Week 2
Change From Baseline at Week 3 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3. Change from baseline: Score at Week 3 minus score at baseline
Time frame: From baseline to Week 3
Change From Baseline at Week 4 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4. Change from baseline: Score at Week 4 minus score at baseline
Time frame: From baseline to Week 4
Change From Baseline at Week 5 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5. Change from baseline: Score at Week 5 minus score at baseline
Time frame: From baseline to Week 5
Change From Baseline at Week 6 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6. Change from baseline: Score at Week 6 minus score at baseline
Time frame: From baseline to Week 6
Change From Baseline at Week 7 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7. Change from baseline: Score at Week 7 minus score at baseline
Time frame: From baseline to Week 7
Change From Baseline at Week 8 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8. Change from baseline: Score at Week 8 minus score at baseline
Time frame: From baseline to Week 8
Change From Baseline at Week 9 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9. Change from baseline: Score at Week 9 minus score at baseline
Time frame: From baseline to Week 9
Change From Baseline at Week 10 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10. Change from baseline: Score at Week 10 minus score at baseline
Time frame: From baseline to Week 10
Change From Baseline at Week 11 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11. Change from baseline: Score at Week 11 minus score at baseline
Time frame: From baseline to Week 11
Change From Baseline at Week 12 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12. Change from baseline: Score at Week 12 minus score at baseline
Time frame: From baseline to Week 12
Change From Baseline at Week 13 in Mean Weekly Pain Scores
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13. Change from baseline: Score at Week 13 minus score at baseline
Time frame: From baseline to Week 13
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Mean Sleep Interference Scores
The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute.
Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Clinical Global Impression of Change
Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: Week 13 or up to discontinuation
Patient Global Impression of Change
The Patient Global Impression of Change is a patient-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: Week 13 or up to discontinuation
| Milestone | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Started | 135 | 134 | 45 |
| Completed | 119 | 114 | 32 |
| Not completed | 16 | 20 | 13 |
| Withdrew: Adverse event | 7 | 17 | 13 |
| Withdrew: Lack of efficacy | 7 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Due to moving | 0 | 1 | 0 |
Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline to Study Endpoint in Mean Weekly Pain Scores | -1.20 ± 0.21 | -1.82 ± 0.22 | -1.94 ± 0.32 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning | 2.70 ± 1.58 | 2.43 ± 1.59 | 3.86 ± 2.33 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical | 4.38 ± 2.47 | 2.28 ± 2.50 | 3.97 ± 3.70 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain | 10.34 ± 1.97 | 11.84 ± 1.99 | 12.89 ± 2.91 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception | 2.31 ± 1.44 | 3.29 ± 1.45 | 4.40 ± 2.14 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning | 3.00 ± 2.39 | 8.06 ± 2.41 | 11.16 ± 3.54 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional | 4.13 ± 2.52 | 5.05 ± 2.55 | 6.35 ± 3.77 |
Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr).
| score on scale | Placebo | Expected Exposure Pregabalin 300 mg/Day | Expected Exposure Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations | -1.27 ± 0.16 | -1.93 ± 0.17 | -1.90 ± 0.25 |
A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint.
| participants | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Number of Responders | 29 | 39 | 16 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1. Change from baseline: Score at Week 1 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 1 in Mean Weekly Pain Scores | -0.39 ± 0.17 | -0.82 ± 0.17 | -1.14 ± 0.26 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2. Change from baseline: Score at Week 2 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 2 in Mean Weekly Pain Scores | -0.57 ± 0.17 | -1.17 ± 0.17 | -1.80 ± 0.26 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3. Change from baseline: Score at Week 3 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 3 in Mean Weekly Pain Scores | -0.80 ± 0.17 | -1.40 ± 0.17 | -1.93 ± 0.26 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4. Change from baseline: Score at Week 4 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 4 in Mean Weekly Pain Scores | -0.89 ± 0.17 | -1.53 ± 0.17 | -2.00 ± 0.26 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5. Change from baseline: Score at Week 5 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 5 in Mean Weekly Pain Scores | -0.91 ± 0.17 | -1.57 ± 0.17 | -2.07 ± 0.27 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6. Change from baseline: Score at Week 6 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 6 in Mean Weekly Pain Scores | -0.94 ± 0.17 | -1.72 ± 0.17 | -2.06 ± 0.27 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7. Change from baseline: Score at Week 7 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 7 in Mean Weekly Pain Scores | -1.04 ± 0.17 | -1.76 ± 0.17 | -2.13 ± 0.27 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8. Change from baseline: Score at Week 8 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 8 in Mean Weekly Pain Scores | -1.18 ± 0.17 | -1.85 ± 0.17 | -2.12 ± 0.27 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9. Change from baseline: Score at Week 9 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 9 in Mean Weekly Pain Scores | -1.20 ± 0.17 | -1.93 ± 0.17 | -2.06 ± 0.28 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10. Change from baseline: Score at Week 10 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 10 in Mean Weekly Pain Scores | -1.23 ± 0.17 | -1.93 ± 0.18 | -2.10 ± 0.28 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11. Change from baseline: Score at Week 11 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 11 in Mean Weekly Pain Scores | -1.32 ± 0.17 | -1.95 ± 0.18 | -2.09 ± 0.28 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12. Change from baseline: Score at Week 12 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 12 in Mean Weekly Pain Scores | -1.36 ± 0.17 | -2.01 ± 0.18 | -2.13 ± 0.29 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality | 5.28 ± 1.92 | 4.20 ± 1.94 | 12.87 ± 2.84 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health | 3.84 ± 1.83 | 5.33 ± 1.85 | 7.81 ± 2.72 |
The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Mean Sleep Interference Scores | -0.74 ± 0.18 | -1.59 ± 0.18 | -1.36 ± 0.27 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores | -2.82 ± 0.50 | -4.60 ± 0.50 | -4.95 ± 0.74 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores | -0.83 ± 0.20 | -1.43 ± 0.20 | -1.39 ± 0.30 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores | -3.68 ± 0.66 | -6.03 ± 0.66 | -6.36 ± 0.97 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain.
| mm | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores | -16.92 ± 2.38 | -24.19 ± 2.40 | -24.41 ± 3.53 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores | -0.59 ± 0.09 | -0.80 ± 0.09 | -0.96 ± 0.13 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance | -9.03 ± 1.86 | -15.40 ± 1.88 | -12.81 ± 2.77 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring | -6.00 ± 2.51 | -5.96 ± 2.53 | -1.56 ± 3.71 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache | -1.63 ± 1.69 | -3.02 ± 1.71 | -4.47 ± 2.51 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep | 0.37 ± 0.12 | 0.69 ± 0.12 | 0.54 ± 0.18 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy | 12.08 ± 2.61 | 17.69 ± 2.64 | 21.73 ± 3.87 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence | -2.96 ± 2.17 | 0.83 ± 2.19 | 4.83 ± 3.20 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute.
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index | -7.91 ± 1.45 | -11.45 ± 1.46 | -9.73 ± 2.16 |
Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Clinical Global Impression of Change | 3.3 ± 1.2 | 2.9 ± 1.1 | 2.7 ± 1.1 |
The Patient Global Impression of Change is a patient-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Patient Global Impression of Change | 3.4 ± 1.3 | 3.2 ± 1.0 | 2.8 ± 1.0 |
The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13. Change from baseline: Score at Week 13 minus score at baseline
| score on scale | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| Change From Baseline at Week 13 in Mean Weekly Pain Scores | -1.38 ± 0.17 | -2.04 ± 0.18 | -2.12 ± 0.29 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/135 (2.2%) | 50/135 (37%) |
| Pregabalin 300 mg/Day | — | 2/134 (1.5%) | 71/134 (53%) |
| Pregabalin 600 mg/Day | — | 1/45 (2.2%) | 36/45 (80%) |
| Event | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | 0/135 | 0/134 | 1/45 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/135 | 0/134 | 1/45 |
| PyrexiaGeneral disorders | 0/135 | 1/134 | 0/45 |
| Brain stem infarctionNervous system disorders | 0/135 | 1/134 | 0/45 |
| Hypertensive encephalopathyNervous system disorders | 0/135 | 1/134 | 0/45 |
| Atrial fibrillationCardiac disorders | 1/135 | 0/134 | 0/45 |
| NauseaGastrointestinal disorders | 1/135 | 0/134 | 0/45 |
| Feeling abnormalGeneral disorders | 1/135 | 0/134 | 0/45 |
| Peripheral coldnessGeneral disorders | 1/135 | 0/134 | 0/45 |
| Herpes zosterInfections and infestations | 1/135 | 0/134 | 0/45 |
| Event | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day |
|---|---|---|---|
| DizzinessNervous system disorders | 9/135 | 26/134 | 18/45 |
| SomnolenceNervous system disorders | 12/135 | 28/134 | 18/45 |
| Oedema peripheralGeneral disorders | 8/135 | 19/134 | 8/45 |
| Weight increasedInvestigations | 5/135 | 17/134 | 7/45 |
| NasopharyngitisInfections and infestations | 20/135 | 16/134 | 4/45 |
| ConstipationGastrointestinal disorders | 1/135 | 4/134 | 3/45 |
| DiarrhoeaGastrointestinal disorders | 5/135 | 3/134 | 3/45 |
| OedemaGeneral disorders | 1/135 | 4/134 | 3/45 |
| Age, Customized(participants) | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day | Total |
|---|---|---|---|---|
| < 18 years | 0 | 0 | 0 | 0 |
| 18 - 44 years | 7 | 8 | 1 | 16 |
| 45 - 64 years | 76 | 78 | 25 | 179 |
| >= 65 years | 52 | 48 | 19 | 119 |
| Age, Continuous(years) | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day | Total |
|---|---|---|---|---|
| Mean | 61.3 ± 9.6 | 61.3 ± 10.3 | 62.2 ± 10.3 | 61.4 ± 10.0 |
| Sex: Female, Male(Participants) | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day | Total |
|---|---|---|---|---|
| Female | 32 | 32 | 13 | 77 |
| Male | 103 | 102 | 32 | 237 |
| Region of Enrollment(participants) | Placebo | Pregabalin 300 mg/Day | Pregabalin 600 mg/Day | Total |
|---|---|---|---|---|
| Japan | 135 | 134 | 45 | 314 |
The record gives a start of Oct 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →